盎格鲁力学 ANGO 深 沪
已收盘 05-15 16:00:00 美东时间
10.77
-0.260
-2.36%
华盛通- 最 高11.09
- 今 开10.96
- 成交量 24.59万股
- 最 低 10.77
- 昨 收 11.03
- 总市值 4.45亿
- 52周最高 13.99
- 市盈率 静 --
- 换手率 0.60%
- 52周最低 8.36
- 委 比 85.01%
- 总股本 4131.89万
- 历史最高 32.00
- 量 比 0.77
- 振 幅 2.90%
- 历史最低 5.26
- 每 手 1
- 风险率 1.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AngioDynamics Announces 2-Yr Results From PRESERVE Pivotal Trial Demonstrating Durable Oncologic Control And Sustained Safety Profile For NanoKnife System In Focal Ablation Of Intermediate-Risk Prostate Cancer
Pivotal U.S. Data Show Sustained Oncologic Control and Safety Profile at 24 monthsResults Presented at AUA 2026AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood flow in
05-13 21:06
Venu Holding plans $300M Chattanooga amphitheater project
Venu Holding (VENU) on Tuesday said it entered an agreement to purchase a 15-acre site in Chattanooga, Tennessee, for the planned development of Sunset Amphitheater Chattanooga, a next-generation live...
05-12 23:18
Sidus Space prices $58.5M offering at $4.35 per share
Space and defense technology firm Sidus Space (SIDU) announced the pricing of a direct offering of ~13.4M shares at an offering price of $4.35 per share. Gross proceeds target $58.5M before placement ...
04-20 12:50
美股大行评级 | 目标价31美元，潜在涨幅64%！多家大行首予PayPay"买入"评级； 大摩上调希捷科技目标价从468美元升至582美元
今日重点评级关注：Canaccord Genuity：维持Taysha Gene Therapies"买入"评级，目标价从14美元升至17美元；Guggenheim：维持天演药业"买入"评级，目标价从9美元升至10美元
04-07 11:53
AngioDynamics Earnings Call Highlights Med Tech Momentum
Angiodynamics, Inc. (($ANGO)) has held its Q3 earnings call. Read on for the ma...
04-06 08:08
AngioDynamics Posts Strong Q3 Results, Raises 2026 Guidance
An update from AngioDynamics ( ($ANGO) ) is now available. On April 2, 2026, An...
04-02 20:12
Earnings Scheduled For April 2, 2026
Companies Reporting Before The Bell • Pharvaris (NASDAQ:PHVS) is estimated to r...
04-02 19:11
AngioDynamics FY26 Q3 net loss widens to $8.1 million; net sales rise 8.9% to $78.4 million
AngioDynamics FY26 Q3 net loss widens to $8.1 million; net sales rise 8.9% to $78.4 million AngioDynamics posted a fiscal 2026 third-quarter net loss of $8.1 million, or $0.19 per share. Net sales rose 8.9% to $78.4 million. Adjusted EBITDA increased to $1.8 million. Med Tech net sales climbed 19% t
04-02 18:02
AngioDynamics Q3 Adj. EPS $(0.07) Beats $(0.11) Estimate, Sales $78.423M Beat $76.767M Estimate
AngioDynamics (NASDAQ:ANGO) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.11) by 36.36 percent. This is a 12.5 percent increase over losses of $(0.08) per share from the
04-02 18:01
